Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard care alone Clear all

Conditions: Osteoarthritis of the Knee
Interventions: Infliximab, Placebo, Standard of Care: Methylprednisolone acetate; Drug
Lead sponsor: Herbert Lindsley, MD; Other
Eligibility: 35 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ischemic Foot Ulcer
Interventions: Endovascular Revascularization; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 110 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-small Cell Lung Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions: VS-01 on top of SOC (Active Treatment Group), SOC; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Dehydration in Children, Dehydration
Interventions: LifeFlow; Device
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 1 Month to 18 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vocal Fold Nodules, Muscle Tension Dysphonia
Interventions: Ambulatory voice biofeedback; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Focal Hyperhidrosis of the Hands
Interventions: BTX-A; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 16 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Late Effects of Surgery, Staphylococcus Aureus, Surgical Site Infection
Interventions: daptomycin; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 19 Years to 74 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Torrance, California

Conditions: Pain Management
Interventions: Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination; Drug
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 3
States / cities: Loma Linda, California • Overland Park, Kansas

Conditions: Non Healing Diabetic Foot Ulcer
Interventions: MolecuLight i:X Imaging Device; Device
Lead sponsor: MolecuLight Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Vista, California • Lake Success, New York • Monroeville, Pennsylvania

Conditions: Myeloproliferative Neoplasms (MPNs)
Interventions: DMR-001, Ruxolitinib; Drug
Lead sponsor: Damora Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 25
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 20 more

Conditions: Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Interventions: Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Heart Failure
Interventions: Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires), Caregiver Self-Assessment; Other · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids; Drug · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 9 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Non Small Cell Lung Carcinoma NSCLC
Interventions: Durvalumab (MEDI4736), Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: AKI, CHD - Congenital Heart Disease, Surgery
Interventions: Nitric Oxide, Oxygen; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Day to 31 Days
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: COVID-19, Sars-CoV2
Interventions: Progesterone 100 MG; Drug
Lead sponsor: Sara Ghandehari; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
Interventions: TTAX01, Standard Care; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: San Francisco, California • Sylmar, California • Miami, Florida + 13 more

Conditions: Obesity, Pain
Interventions: Use of PDA + support to reduce weight and pain, MOVE! level 2 group weight loss counseling; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Hypertension, Pregnancy-Induced, Postpartum Preeclampsia, Hypertension; Maternal
Interventions: Blood Pressure Control Targets, Hypertension Management; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions: Amnion-Intermediate-Chorion, Amnion-Chorion-Amnion, Standard of Care; Other · Procedure
Lead sponsor: Cellution Biologics; Industry
Eligibility: 18 Years to 98 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Jacksonville, Florida • Cincinnati, Ohio • Weslaco, Texas + 1 more

Conditions: Cataracts
Interventions: Xibrom, and Optive, Xibrom and Pred Forte; Drug
Lead sponsor: Bp Consulting, Inc; Network
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tarpon Springs, Florida

Conditions: Multiple Sclerosis
Interventions: Cetirizine, Diphenhydramine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boca Raton, Florida

Search by objective public record fields.

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

Ischemic Foot Ulcers: Is Intervention Better Than Wound Care Alone

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound

Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback

BTX-A Treatment for Palmar Hyperhidrosis

Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain

Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Multidisciplinary Ventricular Assist Device Clinic

Twice Weekly Steroids and Exercise as Therapy for DMD

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

NO During CPB in Neonates to Reduce Risk of AKI

Progesterone for the Treatment of COVID-19 in Hospitalized Men

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

PDA+: A Personal Digital Assistant for Obesity Treatment

Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy

The Effects of Indocyanine Green Angiography (IGA) on Deep Inferior Epigastric Artery Perforator (DIEP) Flap Design and Post-Operative Fat Necrosis

Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project